

## Response Letter

Dear editor and reviewers,

We appreciate that you give us the opportunity to revise our manuscript. We also thank the editor's and reviewers' valuable comments. The manuscript has been revised accordingly and we hope that it fits the requirements of *World Journal of Gastrointestinal Surgery*.

### Point-to-point response:

#### Review Comments

#04054541

Specific Comments To Authors:

In this review, the authors summarized the current knowledge about the employment of RAPA after liver transplantation due to hepatocellular carcinoma. They explored also the possibility to combine RAPA therapy with other drugs to evaluate the beneficial effects. The paper is generally well written and discussed. I suggest only a minor revision to correct some oversights in the text that I listed below.

**Comment 1:** On page 3, line 11, the preposition "in" before the word "comparison" is needed.

**Reply 1:** Thanks for pointing this out. The preposition "in" has been added.

**Comment 2:** On page 5, line 5, I suggest citing both the authors of the work of 1989: Meiser and Morris.

**Reply 2:** Thanks for the suggestion. The citation format has been modified.

**Comment 3:** On page 5, line 8, the verb "opens" is referred to as a plural name, so it should be written without the final "s".

**Reply 3:** Thanks for pointing this out. The final "s" has been deleted.

**Comment 4:** On page 5, line 27, the spaces between the slash and the (p70S6K) and the word ribosomal should be eliminated. The same error appears in line 29 and line 1 on page 7.

**Reply 4:** Thanks for pointing this out. The word "ribosomal" have been deleted.

**Comment 5:** On page 7, line 12, the verb "is" should be introduced before the word "responsible".

**Reply 5:** Thanks for pointing this out. The verb "is" has been added.

**Comment 6:** On page 8, the acronym PI3K is written P13K twice. Please correct them.

**Reply 6:** Thanks for pointing this out. This error has been corrected.

**Comment 7:** On page 8, after point 2 the capital letter is needed. Moreover, extra space is present before the point 3, please remove it.

**Reply 7:** Thanks for pointing this out. These errors have been modified.

**Comment 8:** On page 10, please correct "Marta" with Guerrero that is the surname of the author. Marta is the first name.

**Reply 8:** Thanks for pointing this out. This error has been corrected.

**Comment 9:** On page 11, after reference 47 there is an extra space, please remove it.

**Reply 9:** Thanks for pointing this out. This error has been corrected.

**Comment 10:** On page 11, please put the symbol " $\geq$ " before the number 10.

**Reply 10:** Thanks for pointing this out. This error has been corrected.

**Comment 11:** On page 15, the two brackets with "unpublished data" have two additional spaces, please remove them.

**Reply 11:** Thanks for pointing this out. Two additional spaces have been removed.

**Comment 12:** At page 18, after the word "secondly," the word "chemical" should have the lower letter.

**Reply 12:** Thanks for pointing this out. These errors have been modified.

#04737371

Specific Comments To Authors:

We have read the review article by Zhao and colleagues regarding a pertinent topic. The review is well written, concise. However we have comments regarding the review

**Comment 1:** Discussion on everolimus should be added as that has been advocated as one of the main stays in treatment of post liver transplant HCC recurrence.

**Reply 1:** Thanks for the suggestion. Discussion on everolimus have been added. (page 12 line 23-page 13 line 5)

**Comment 2:** A Figure should be added regarding the pathophysiology/Functions of RAP in post transplant patients

**Reply 2:** Thanks for the suggestion. A Figure has been added.

**Comment 3:** All the studies on rapamycin animal/clinical should be in an tabular form

**Reply 3:** Thanks for the suggestion. A table has been added.

**Comment 4:** A proposed treatment algorithm regarding the recommendations of the author to be added

**Reply 4:** Thanks for the suggestion. A proposed treatment algorithm has been added. (page 18 line 1-page 18 line 30)

**Comment 5:** Limitations/Adverse effects regarding Rapamycin should be discussed

**Reply 5:** Thanks for the suggestion. Adverse effects regarding RAPA have been discussed. (page 12 line 10-22)

If any new comments, please feel free to contact me.

Sincerely yours,

Corresponding author:

Guo-sheng Du, MD, Professor

Faculty of Hepato-Pancreato-Biliary Surgery,

Chinese PLA General Hospital

Address: Faculty of Hepato-Pancreato-Biliary Surgery, Chinese PLA General Hospital,  
Beijing 100853, China.

E-mail: [duguosheng309@126.com](mailto:duguosheng309@126.com)

Tel: 86-010-85231504

Fax: 86-010-85231503